1. business and industrial
2. business operations
3. business plans

2009
OPTIMIZE OPERATIONAL EFFICIENCIES
PROTECT SAMPLE INTEGRITY FOR THE FUTURE
UNCOVER THE LIMITLESS POSSIBILITIES
DECREASE YOUR OPPORTUNITY RISK
© 2009 Institute for International Research, Inc. All rights reserved
September 21-23, 2009
Park Hyatt, Philadelphia, PA
www.biorepositoriesevent.com
w w w. b io rep o si t o ri e se ve n t .co m
1
The nation’s leading biobanking experts gather annually at The Biorepositories event to
cultivate a strategic perspective on biorepository sample management and discuss best
practices for improving storage, distribution, and tracking to protect, prove, and validate
sample integrity throughout the entire drug development process. Join them this year to obtain:
• Updates and direction on future industry guidelines and regulations
• Strategies to integrate the best and next industry practices into your biobank from the
leading industry experts who are driving innovation in the field of biorepositories
• T ools to implement new technologies and procedures to be more time and cost efficient
in this economy
• Operational Strategies, Software Management Systems, Sample Integrity, Sample
Procurement, and Practical Solutions that will infuse new energy into your Biorepository
There is no other event of this kind which sold out last year! Don’t miss this premier event in
September 2009!
Who Will You Meet?
The Biorepositories conference is designed for individuals from the Pharma and Biotech industries
including: Vice Presidents, Directors, and Managers in the following departments/areas:
• Biorepository Operations
• Procurement and Strategic Sourcing
• Biobanking Operations
• Strategic Outsourcing
• Sample Management
• Clinical Research
• L
aboratory and Inventory Management
• Translational Medicine
• R&D
• Personalized Medicine
• Quality Control
• Bioanalytical Chemistry
Crystal Dotson, Banking Process
Expert/Diagnostic and Experimental
Medicine, ELI LILLY & COMPANY
Fred Leeds, Associate Director,
Global R&D Procurement,
BRISTOL-MYERS SQUIBB
Andrew Mills, Global Director
of Marketing and Commercial
Operations, BIOSTORAGE
TECHNOLOGIES
Amelia Wall Warner, PharmD,
RPh, Senior Principal Scientist,
SCHERING-PLOUGH
CORPORATION
Start Networking on Biorepositories’
www.linkedin.com/groups?gid=1821976
Start Networking on Biorepositories’
• Pharmacogenomics
2008 Delegate Job Function
Other 5%
Distinguished Members
of the Advisory Board
www.researchgate.net/groups.GroupInfo.
html?group=2986
Operations and Sample Management 39%
Follow us on Twitter
Biological and
Translational science
21%
Research and Development 35%
www.twitter.com/futureofbiopharma
“The workshops appear to be at a threshold of a new topic in science and business that is only now just being addressed in
standardizing the handling of samples.”
Duncan Wallace, Gilead Sciences Inc.
“Excellent agenda”
Marylee Garvey, Biogen Idec
“This is the first opportunity I have seen to get together with others who work in the field to discuss issues I worry about every day.”
Sascha Ellers, Genentech
“It was a wonderful conference. It certainly improved my knowledge of many aspects around sample collections, storage, and
shipping.”
Joanna Thomas, Roche
“The mix of industry and academia was excellent.”
2008 attendee
2
Phone: 888.670.8200 Fax: 941.365.2507 Email: [email protected]
Monday, September 21
Conference Symposium and Workshops
Full Day Symposium
B1
Obtain Appropriate Informed Consent for Optimal Usage of Biorepository Samples and Create Templates For Maximum Efficiency
8:00
9:00
10:30
12:30
Registration and Morning Coffee
Symposium Begins
Morning Networking Break
Networking Luncheon for Symposium attendees
1:30
3:00
4:30
Obtaining and managing informed consent during clinical trials
is crucial for the testing of samples down the road. This session
covers the latest practices and challenges when dealing with
informed consent.
• What are the basic elements of informed consent for future
sample use?
• Standardization of consent forms - do standards exist?
• How do you incorporate patient privacy into informed consent?
• Internal Review Board (IRB) Challenges – how to handle
variability
Symposium Continues
Afternoon Networking Break
Symposium Concludes
• IRB perspective of their interpretation of ICFs they review and
issues they see
• Linking informed consent to the clinical information and the
sample
• How to collect, manage and track informed consent
Facilitators/Speakers
Amelia Wall Warner, PharmD, RPh, Senior Principal Scientist,
SCHERING-PLOUGH CORPORATION
Ellen Kelso, Chief Executive Officer, GOODWYN IRB
Elaine Moorman, Program Manager, Clinical Laboratory Project
Manager, PROCTER & GAMBLE
Half Day WorkshopS
B2
B uild a Biorepository from the Ground Up: Practical
Measures for Incorporating a Biorepository in Your
Organization
8:00
9:00
10:30
12:30
Registration and Morning Coffee
Workshop Begins
Morning Networking Break
Networking Luncheon for Workshop attendees
© 2009 Institute for International Research, Inc. All rights reserved
How do you build an efficient, sustainable biorepository that fulfills
best practice guidelines and offers high utility? How do you do this
in tough economic times?
This introductory workshop explores the need for biospecimen
resource as well as the benefits for having a storage facility in
house. Industry leaders discuss the current state of Biorepositories
today and discuss the necessary requirements, planning,
management and other prerequisites to develop and operate
biospecimen resource core facility.
• Choosing the right equipment for your biorepository
• Developing evidence based protocols for sample collection and
processing
• Staffing your biorepository with the appropriately trained
personnel
• Establishing the scope of the biobank collections
• Defining & identifying BIMS/LIMS system needs
• Economic Strategies for development
Industry Working Group: Creating and Adhering to
B3 Standards for Biorepository Operations to Achieve
High Quality Results and Data
1:00
1:30
3:00
4:30
•
•
•
•
Afternoon Workshop Registration
Workshop Begins
Afternoon Networking Break
Workshop Concludes
Overview of NIH and ISBER guidelines
How to develop universal standards for the industry
Standards for storage temperature
How long should a sample be stored and what is the stability of
samples stored for different lengths of time?
Helen M. Moore, PhD, Biospecimen Research Network Program
Manager, Office of the Director, NATIONAL CANCER INSTITUTE
Andrew I. Brooks, PhD, Associate Professor of Environmental
Medicine and Genetics Director, Bionomics Research and Technology
Center Environmental and Occupational Health Science Center RWJUMDNJ, RUTGERS UNIVERSITY
Lori A. Ball, MBA, Senior Vice President, BIOSTORAGE
TECHNOLOGIES
Marielena Mata, Senior Research Scientist/Biobank Manager,
Biomarkers, CENTOCOR
Leonardo Sahelijo, MD, Medical Director, Pharmacogenomics,
TAKEDA GLOBAL RESEARCH & DEVELOPMENT CENTER
Lisa B Miranda, President, BIOBUSINESS CONSULTING
formerly Technical Director, TTAB Facility, University of
Pennsylvania
w w w. b io rep o si t o ri e se ve n t .co m
3
Tuesday, September 22
7:30
Conference Registration and Morning Coffee
8:00
Co-chairpersons’ Welcome and Opening Remarks
Diane Johnson, Associate Director, PFIZER’S DNA & BIOFLUIDS
CENTER OF EMPHASIS
John Mills, MD, PhD, Chief Executive Officer, BIOSTORAGE
TECHNOLOGIES
8:15
Developing The Underlying Science Necessary For
Successful Biobanking
Hear from the National Cancer Institute’s Office of Biorepositories
and Biospecimen Research as Helen Moore discusses the NCI
research program in biospecimen science, the Biospecimen
Research Network.
• What does our current scientific evidence show us about
biobanking?
• What additional evidence is needed to ensure we improve our
biobanking process?
• How do you assess whether the specimens in your biobanks are
reasonable choices for collection?
Helen M. Moore, PhD, Director, Biospecimen Research Network,
Biorepositories and Biospecimen Research, NATIONAL CANCER
INSTITUTE
9:00
10:15
Best Practices for Evaluating the Value of Specimen
Collections: When and How To Make Decisions About
Maintaining Or Culling Specimen Collections
Compliance with industry best practices and guidelines for
collecting, storing, and testing samples is critical for successful
drug development. Hear from the most recent recommendations
from the International Society for Biological and Environmental
Repositories (ISBER) and the National Cancer Institute on this
important topic. Gain insights to new tools to help you determine
how compliant you are with these guidelines. Also hear the latest
on sample culling and maintaining sample integrity.
• How can standardization increase the likelihood that sample
integrity is maintained?
• What factors should you consider when deciding if samples
should be kept or destroyed?
Karen Pitt, PhD, Special Assistant for Biological Resources,
NATIONAL CANCER INSTITUTE
11:00
FDA
IPWG White Paper Discussion
IPWG polled all of the major pharmaceutical companies to collect
the following information:
• What samples are being collected and why?
• Which phase(s) should samples be collected?
Hear directly from an author of the white paper to discover best
collection practices to consider for your studies.
Amelia Wall Warner, PharmD, RPh, Senior Principal Scientist,
SCHERING-PLOUGH CORPORATION
9:45
General Session
30 Minute Morning Networking Break
Biospecimen Quality in Regulatory Submissions
FDA is increasingly aware of the potential for test results to be
compromised by poor quality biospecimens or biospecimen
processing, both in in vitro diagnostic device performance, and in
the performance of tests used to support therapeutic application
claims. Recommendations for biospecimen quality principles
are being incorporated into FDA guidances, and should result in
greater confidence in test results in regulatory submissions. Clear
biospecimen quality parameters for IVD testing will also support
more reliable clinical laboratory test results, and ultimately, better
patient care.
Elizabeth Mansfield, PhD, Senior Policy Advisor, Office of In Vitro
Diagnostic Devices, CDRH/FDA
11:45 Panel Discussion: Biorepository Standardization
• Are you up to speed on guidelines and compliance?
• How can you apply the best practices to your Biorepository?
• How can you guarantee accurate data for the future use of your
sample?
A panel discussion from this morning’s speaking faculty.
12:30
Networking Luncheon
CONCURRENT BREAK OUT SESSIONS
A
1:30
Grow your biorepository from
a collection into a strategic asset
Shaping the Biorepository for the New Millennium
Over the past decade Millennium’s biorepository has evolved to a
state of the art Sample Management LIMS System with improved data
capture and scientific ontology categorization. Throughout this process
the biorepository has reduced its footprint by 50% and undergone
reconciliation of physical and electronic inventories. Millennium focused
on the following three areas:
• Electronic Records: Data migration and standardized accurate sample
annotation, sample X-Y location and chain of custody tracking, audit
trail analysis.
• Physical Space: Managing increasing inventory in finite space,
consolidating a vast specimen collection to a focused collection,
storing archived collections offsite and employing an efficient
outsourcing model for assay testing.
• Sample Integrity: Assessing sample quality based on age, number of
times used, freeze/thaw, visual inspection and qualitative assessment
performed on the molecular level.
Erik Koenig, Senior Manager, Molecular Technologies,
MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
4
B
DIVERSIFY YOUR BIOBANK
Gain Insights to How The Indiana Health Study Can Gain You
Access To New Patient Populations
The Indiana Health Study is a longitudinal study of the population of
Indianapolis designed to create a novel research platform (biorepository)
to be made available for commercial and academic research aimed at
finding better ways to diagnose and treat common chronic diseases such
as heart disease, diabetes and cancer. The research platform is unique
due to its
• focus on the Indianapolis population, a diverse, health challenged
community
• partnership with the Regenstrief Institute at Indiana University School
of Medicine, a group internationally recognized for their medical
informatics capabilities
•plans to follow study participants through both annual telephone
interviews and the electronic medical record
Cynthia Helphingstine, PhD, President and COO,
THE FAIRBANKS INSTITUTE FOR HEALTHY COMMUNITIES
Phone: 888.670.8200 Fax: 941.365.2507 Email: [email protected]
A
2:15
Grow your biorepository from
a collection into a strategic asset
B
DIVERSIFY YOUR BIOBANK
Best Practices for Creating a Sample “Store”
Increase the Diversity of Your Biobank
As you are setting up and running a biorepository, it is essential to think
about who will be using your services and how you can reach out to them
as customers. This presentation will present some lessons learned from
efforts to establish the Genentech Sample Repository and communicate
our role and services throughout the company.
• Who are your customers?
• What are their current needs?
• What will their needs be in the future?
• How can you anticipate their needs?
Expand your biorepository by procuring samples to tremendously
increase the value of your sample data collection.
• Gain access to unique samples and cell lines
• Establish virtual biobanks
• Overcome hurdles in collecting and distributing samples
• What are the challenges with fee based specimen collection and
distribution?
Joseph L. Mintzer, Executive Vice President, Chief Operating Officer,
CORIELL INSTITUTE FOR MEDICAL RESEARCH
Diane Leong, Ph.D, Associate Director, Sample Repository,
GENENTECH
3:00
Ensuring Service Excellence in your Biorepository to Maximize
Value to all Stakeholders
Panel Discussion: Partnering in Biobanking – Establish
Connections to Expand Your Access to Patient Populations
To run and manage a successful biorepository that can add to your
organization’s bottom line, it is essential to understand the special needs
of your internal and external partners. Now more than ever before,
expectations in safety, integrity and quality are higher and clinical study
managers are under increasing pressure to ensure everything is done
right the first time, throughout every step, from sample collection, testing,
transportation, and storage. In this session, experts provide insights and
strategies to:
• Implement an advanced QA program which continually assesses and
controls the quality of repository services to ensure sample integrity
• Ensure optimal collection from supplies acquisition, tracking and
distribution
• Improve management of biological samples including complex
aliquoting, blood processing and buccal cell collection and processing
• Streamline cold chain transport and relocation in global trials to meet
the needs of global customers
Mike Adams, Director of Marketing, FISHER BIOSERVICES
Gaining access to public biobanks can be very beneficial to drug
development and clinical testing. Scientists are able to acquire additional
information about patient populations by accessing these additional
collections. Hear from our panel of non-industry biobank experts on
how you can collaborate with academics, hospitals, and non-profit
organizations to increase your sample collection.
Panelists
Joseph L. Mintzer, Executive Vice President, Chief Operating Officer,
CORIELL INSTITUTE FOR MEDICAL RESEARCH
Cynthia Helphingstine, PhD, President and COO, THE FAIRBANKS
INSTITUTE FOR HEALTHY COMMUNITIES
Andrew I. Brooks, PhD, Associate Professor of Environmental Medicine
and Genetics Director, Bionomics Research and Technology Center
Environmental and Occupational Health Science Center RWJ-UMDNJ,
RUTGERS UNIVERSITY
3:45
30 Minute Afternoon Networking Break
4:15
Panel Discussion: Outsourcing Strategies for Sample Management
Is your company considering outsourcing part or all of your Biorepository needs?
• What challenges will you encounter?
• How can you build an effective relationship with your vendor?
• What factors should be considered when evaluating service providers?
Erik Koenig, Senior Manager, Molecular Technologies, MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
Rose Sekulovich, Director, BioAnalytical, AMYLIN
Laura Faron-Yowe, Sr. Research Associate, Molecular Technologies, MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
5:00
© 2009 Institute for International Research, Inc. All rights reserved
Networking Reception Hosted by
Wednesday, September 23
7:30
Conference Registration and Morning Coffee
8:00
Co-chairpersons’ Recap of Day One
Diane Johnson, Associate Director, PFIZER’S DNA & BIOFLUIDS
CENTER OF EMPHASIS
John Mills, MD, PhD, chief Executive Officer, BIOSTORAGE
TECHNOLOGIES
8:15
Data Privacy and the Related Ethical Issues - Keeping
the Promise to Society of Genetic-based Research While
Honoring the Assertion of Individual Privacy Rights
Data privacy is a significant barrier to global sample collection
and has been a launching point for many difficult questions. This
session seeks to open the dialogue that will be necessary to identify
General Session
the legal, regulatory, policy and ethical changes required to realize
the full potential of the future of drug discovery and manage the
protection of patient privacy.
• Should individuals have the right to “control” de-identified
samples?
• Can samples truly be “de-identified?”
• Is traditional consent ethical if the nature of the use can’t be
readily explained in lay terms?
• If you have a sample bank linked to identifiable individuals, how
do you manage various rights?
Stanley W. Crosley, CIPP, Chief Privacy Officer, Assistant General
Counsel, ELI LILLY
w w w. b io rep o si t o ri e se ve n t .co m
5
Wednesday, September 23
9:00
Establish a High Standard of Collection Practices to
Ensure Sample Viability
Proper sample collection processes begin well before the first
clinic visit. Critical parameters should be assessed during the
method validation procedures. All of these parameters contribute
significantly to the overall integrity of the sample during the
collection, processing, storage and analysis scenario.
• Do the samples need to be chilled immediately after sample
collection and during any post-collection processing steps?
• Have various anticoagulants been explored in order to optimize
stability of plasma samples to be collected during the trial?
• How thermally labile is the specimen during the sample analysis
process?
• How long is the sample stable at -20oC, -80oC or at the selected
storage temperature?
• Can the sample be clearly identified as a discrete, unique entity
at any time during the lifecycle of the sample?
General Session
biospecimen samples? Hear our expert panelists discuss
challenges with transporting sensitive material.
• Are personnel trained correctly?
• Is the temperature during shipment being tracked?
• If a shipment is delayed, will it be kept in the right temperature?
• How do you ensure sample quality when shipping internationally?
Elaina Mann, Manager, Translational Medicine, CELGENE
Jerry Chang, Director of Operations,
AXOGEN NERVE REGENERATION
12:30
Networking Luncheon
1:30 Best Practices For Biobanking: A Standardized
Biospecimen Management Database for The Arizona
Cancer Center’s Prostate Cancer Research Program
The Arizona Cancer Center coordinates the best practices use of
patient biologics and their clinical and epidemiological data so that
advances in prevention, detection, biology, and the treatment of
prostate cancer can be rapidly achieved. To expand the center’s
efforts and to optimize the use of these high value samples, our
center has implemented a customized version of the GenConnect
biosample management software to streamline and enhance the
process of storing, retrieving and sharing biologic specimens for
research purposes. This sessions will emphasize:
• Existing software capabilities
• Customization carried out to introduce clinical and
epidemiological data into the database
• Standardization using caBIG and NCI Best Practices for
Biospecimen Resources guidelines
John MacNeela, Manager of Laboratory Operations,
GILEAD SCIENCES
9:45
30 Minute Networking Break
10:15 Challenges In Sample Management When Implementating
Longitudinal Biomarker Testing
Sample stability is critical for longitudinal clinical testing, especially
with respect to exploratory biomarker studies. This session
discusses the impact of sample collection procedures and sample
storage quality on results interpretation.
• The impact of sample collection and storage with respect to
biomarker testing
• Data interpretation in the context of assay performance and
sample management over time
Crystal Sung, PhD, D(ABMLI), Scientific Director,
GENZYME CORPORATION
11:00
Panel Discussion: Cutting Insights on Going Green in Your
Biorepository
Have you considered how the energy footprint and design of your
facility may impact the environment? How can you design your
biorepository to be eco-friendly? How can you protect your samples
and the environment? Hear our expert panelists discuss new
technology focusing on energy efficiency while maintaining sample
integrity.
Patricia Thompson, PhD, Assistant Professor,
ARIZONA CANCER CENTER
2:00 Establish a Reliable Informatics System to Track Samples
and Data - Buy vs. Build
Validated sample management systems are crucial to the success of
your Biorepository. Do companies have the appropriate information
to do the kind of forward thinking science that will need to be done
with biorepositories samples? Hear strategies for determining the
appropriate software for your company’s needs.
• What systems exist to manage clinical information?
• Determining cost in hours, manpower and experience
• Software validation – meeting regulatory guidelines
• How best to implement a management system in new and
currently operating environments
• Avoid pitfalls by hearing lessons learned from those who created
or customized their own system
Edward P. Frantz, Jr., National Sales Director, ENVIRONMENTAL
SPECIALTIES
Diane Johnson, Associate Director, PFIZER’S DNA & BIOFLUIDS
CENTER OF EMPHASIS
James B. Matthew, PhD, JB MATTHEW CONSULTING LLC,
formerly Executive Director of Exploratory Medicinal Science,
PFIZER
11:45 Panel Discussion: Optimum Transportation Practices to
Ensure the Safety and Quality of Your Sample
Jon Newman, Senior Sample Logistics Administrator,
ZYMOGENETICS
Jennifer Benner, Manager of Quality Systems,
BIOSTORAGE TECHNOLOGIES
3:00
Conference Concludes
What factors should be considered when transporting fragile
BIOREPOSITORIES 2009 offers you an excellent opportunity to showcase your product in front of key decisionmakers. Morning and afternoon breaks are carefully designed to ensure maximum networking opportunities, and all
the exhibits are strategically positioned to ensure excellent traffic.
Maximize your marketing dollars by exhibiting at the event, or increase your exposure even further by sponsoring a
cocktail reception, luncheon or breakfast.
To learn more about sponsorship opportunities, please call Business Development Manager, Andrew Sinetar at
646-895-7484; E-mail at [email protected]. To learn more about exhibiting, please call Business Development
Manager, David Borrok at 646-895-7485; E-mail at [email protected].
6
Phone: 888.670.8200 Fax: 941.365.2507 Email: [email protected]
PLATINUM SPONSOR
recovery, associated data entry and mining, and distribution of DNA and RNA at room
temperature. With GenPlates, GenSolve, GenConnect software, and the Dynamic
Archive, GenVault is innovating best practices for biosample management and
preservation. Learn more at www.genvault.com.
BioStorage Technologies, Inc. is a worldwide leader in sample storage, inventory
management and cold chain logistics for the biotechnology and pharmaceutical
industries throughout the research, clinical trial and commercialization phases of drug
development. The company offers secure, temperature-controlled storage; real-time
tracking of stored biological samples; and next-day return of biomaterials. BioStorage
Technologies is privately held and headquartered in Indianapolis with an additional
full-service site near Frankfurt, Germany. For more information, visit www.biostorage.
com or call +1 (866) 697-2675 or +49-6155-898-1010.
**Brochure photos courtesy of BioStorage Technologies Inc
SPONSORS
Fisher BioServices is the world leader in
biological specimen management
supporting all sectors of the life science and
drug development industries including;
Pharmaceutical, Biotech, Academia and Government. We provide customized
solutions for specimen kit assembly and collection, cold-chain transport, lab
processing, biobanking and repository services that ensure our customers’ success
and peace of mind.
GenVault is the global leader in providing biosample
workflow, transport, and storage solutions for genomic
medicine, discovery, and identification. The company’s
dry‐state platform enables the collection, preservation,
Media Partner
Environmental Specialties (ES), a Bahnson
Group Company, is a leading manufacturer of
high volume custom low temperature Reach-In
and Walk-In Freezers serving the pharmaceutical/biotech industry, government
agencies, contract biorepositories, academic institutions and other critical product
storage industries. ES is active in supplying the leading automated high throughput
screening advanced automation companies with custom chambers and refrigeration
systems integrated into their total offering.
Manufacturing is located in Raleigh, North Carolina and service/installation teams
operate throughout North America. For a complete review of our broad offering of
controlled environmental/stability rooms/chambers, services and applications, please
view our website at: www.eschambers.com.
Covance, with headquarters in Princeton, New
Jersey, is one of the world’s largest and most
comprehensive drug development services
companies, with annual revenues greater than $1.7 billion and more than 9,600
employees in over 25 countries. Covance has the people, processes, client service
and global resource capabilities to respond to biotechnology and pharmaceutical
clients’ toughest drug development challenges.
With the most comprehensive portfolio of preclinical, clinical development and
commercialization services, Covance provides industry-leading services, the
world’s largest central laboratory network, and a global team of clinical trial and
commercialization experts.
Exhibitors
4 Easy Ways to Register
Call
Fax
888.670.8200 US or 941.951.7885 Int’l
E-Mail
941.365.2507
Standard
Rate
Before
7/10/09
Before
8/7/09
Before
9/4/09
After
9/4/09
Supplier/
Vendor
Gov/
Acedemic
Conference Only
$1995
$2095
$2195
$2395
$2395
$1595
Conference Plus
One Workshop
$2295
2395
$2495
$2695
$2695
$1795
Conference Plus
Two Workshops/
Symposium
$2495
$2595
$2695
$2895
$2895
$1995
© 2009 Institute for International Research, Inc. All rights reserved
Payment is due within 30 days of registering. If registering within 30 days of the
event, payment is due immediately. You may pay by check, VISA, MasterCard,
Discover, Diner’s Club or American Express. Please make all checks payable to the
“Institute for International Research, Inc.” and write the name of the delegate(s)
and our reference number P1498 on the face of the check. If payment has not been
received prior to registration the morning of the conference, a credit card hold will
be required.
DATES: September 21-23, 2009
VENUE: P
ark Hyatt Philadelphia at the Bellevue
200 South Broad Street
Philadelphia, Pennsylvania 19102
Tel: 215 893 1234
Book Early!
Hotel Will Sell Out
HOTEL ACCOMMODATIONS: All hotel bookings must be made directly with the
hotel by calling 800-778-7477. Please inform the registration agent that you are
attending the IIR – BioRepositories Conference to attain the negotiated rate. Please
note: This room rate is exclusive of applicable taxes. Subject to availability, this
rate will be offered three days prior and after conference dates. The cut off date for
reservations is Friday, August 21, 2009.
DRESS CODE: Business casual attire is suggested. We recommend bringing a
sweater or jacket, as the conference rooms may be cool.
Incorrect Mailing Information?
If you are receiving multiple mailings, have updated information or would like to be
removed from our database, please contact us at (212) 661-3876. Please keep in
mind that amendments can take up to 6 weeks.
[email protected]
Web
www.biorepositoriesevent.com
Cancellation Policy: If you need to make any changes or have any questions, please
feel free to contact us via email at [email protected]. Cancellations must be in writing
and must be received by IIR prior to 10 business days before the start of the event. Upon
receipt of a timely cancellation notice, IIR will issue a credit voucher for the full amount
of your payment, which may be applied towards registration fees at any future IIR event
held within 12 months after issuance (Expiration Date, September 21, 2010). All credit
vouchers shall automatically expire on the Expiration Date and shall thereupon become
void. In lieu of issuance of a credit voucher, at your request, IIR will issue a refund less a
$795 processing fee per registration. Registrants are advised that no credit vouchers or
refunds will be issued for cancellations received less than ten business days prior to start of
the event, including cancellations due to weather or other causes beyond the Registrant’s
control. IIR therefore recommends that registrants allow for unexpected delays in making
travel plans. Substitutions are welcome at any time.
If for any reason IIR decides to cancel this conference, IIR accepts no responsibility for
covering airfare, hotel or other costs incurred by registrants, including delegates, sponsors,
speakers and guests. Program content is subject to change without notice. All speakers and
topics are confirmed as of press time. When substitutions must be made due to speaker
cancellations, IIR makes every effort to find a replacement of equal caliber to present the
scheduled topic. Press permission must be obtained prior to the event and is dependent
upon the speakers’ approval. The press may not quote speakers or delegates unless they
have obtained their approval in writing. Press passes do not include admittance to preevent workshops and symposia. For General Information Inquiries, e-mail us at
[email protected].
Any disabled individual desiring auxiliary aid for this conference should notify IIR
at least 3 weeks prior to the conference in writing, by faxing to (212) 661-6045.
EVENT DOCUMENTATION ORDER: If you are unable to attend the program, or would
simply like to order additional sets of documentation for your colleagues, they are available
for $495 per set. The documentation is a compilation of the speaker presentations including
overheads, power point presentations, articles and charts. The documentation is available
online two weeks after the event takes place. Credit Card Payments Only.
GROUP DISCOUNTS AVAILABLE- SEND YOUR WHOLE TEAM!
Send 3 individuals from the same company and each receives 10% off the standard rate. All
individuals must register at the same time. For further information, contact Aloycia Bellillie
at 646.895.7410, or email [email protected]. No two discounts can be combined.
w w w. b io rep o si t o ri e se ve n t .co m
P1498
7
Institute for International Research
708 Third Avenue, 4th Floor
New York, NY 10017-4103
PLATINUM SPONSOR
SPONSORS
PRSRT STD
U.S. Postage
PAID
IIR
Please Do Not Remove Mailing Label
2009
Media Partner
OPTIMIZE
Exhibitors
OPERATIONAL EFFICIENCIES
PROTECT SAMPLE INTEGRITY FOR THE FUTURE
P1498
UNCOVER THE LIMITLESS POSSIBILITIES
2009
DECREASE YOUR OPPORTUNITY RISK
OPTIMIZE OPERATIONAL EFFICIENCIES
PROTECT
SAMPLE INTEGRITY
FOR THE FUTURE
OPTIMIZE
OPERATIONAL
EFFICIENCIES
UNCOVER THE LIMITLESS POSSIBILITIES
DECREASE YOUR OPPORTUNITY RISK
PROTECT SAMPLE INTEGRITY FOR THE FUTURE
September 21-23, 2009
Park Hyatt, Philadelphia, PA
UNCOVER THE LIMITLESS POSSIBILITIES
www.biorepositoriesevent.com